Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DGA cream for prevention of sunitinib-induced hand-foot skin reaction in renal cell carcinoma
jRCTs051180051Phase 2Completed
- Sponsor
- Momotani Juntenkan
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amitose-bisglyceryl ascorbic acid in renal cell carcinoma (RCC), Hand-foot skin reaction (HFSR) and Erythrodysesthesia syndrome (PPE), sponsored by Momotani Juntenkan. Started Nov 2017; status: completed.
02
Drugs
amitose-bisglyceryl ascorbic acid
03
Conditions
renal cell carcinoma (RCC)Hand-foot skin reaction (HFSR)Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on jRCTs051180051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180051.